0001615774-17-004154.txt : 20170808 0001615774-17-004154.hdr.sgml : 20170808 20170808163036 ACCESSION NUMBER: 0001615774-17-004154 CONFORMED SUBMISSION TYPE: SC 13G PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20170808 DATE AS OF CHANGE: 20170808 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: AMYRIS, INC. CENTRAL INDEX KEY: 0001365916 STANDARD INDUSTRIAL CLASSIFICATION: INDUSTRIAL ORGANIC CHEMICALS [2860] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G SEC ACT: 1934 Act SEC FILE NUMBER: 005-85969 FILM NUMBER: 171015223 BUSINESS ADDRESS: STREET 1: 5885 HOLLIS ST SUITE 100 CITY: EMERYVILLE STATE: CA ZIP: 94608 BUSINESS PHONE: 510-450-0761 MAIL ADDRESS: STREET 1: 5885 HOLLIS ST SUITE 100 CITY: EMERYVILLE STATE: CA ZIP: 94608 FORMER COMPANY: FORMER CONFORMED NAME: AMYRIS BIOTECHNOLOGIES INC DATE OF NAME CHANGE: 20060613 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: Vivo Capital VIII, LLC CENTRAL INDEX KEY: 0001618789 IRS NUMBER: 471761992 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G BUSINESS ADDRESS: STREET 1: 505 HAMILTON AVENUE, SUITE 200 CITY: PALO ALTO STATE: CA ZIP: 94301 BUSINESS PHONE: 650 688 0822 MAIL ADDRESS: STREET 1: 505 HAMILTON AVENUE, SUITE 200 CITY: PALO ALTO STATE: CA ZIP: 94301 SC 13G 1 s107079_13g.htm SC 13G

United States

 

Securities and Exchange Commission

 

Washington, D.C. 20549

 

 

 

SCHEDULE 13G

 

Under the Securities Exchange Act of 1934

 

(Amendment No. )* 

 
Amyris, Inc.
(Name of Issuer)
 
Common Stock
(Title of Class of Securities)
 
03236M101
(CUSIP Number)
 
August 2, 2017
(Date of Event which Requires Filing of this Statement)

 

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

 

☐       Rule 13d-1(b)

 

☒       Rule 13d-1(c)

 

☐       Rule 13d-1(d)

 

 

*The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

 

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

 

 

CUSIP No. 03236M101
1 NAMES OF REPORTING PERSONS
Vivo Capital VIII, LLC
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP  (See Instructions)  
(a)      ☐      
(b)      ☐      
3 SEC USE ONLY
 
4 CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON
WITH
5 SOLE VOTING POWER
2,826,711 (1)
6 SHARED VOTING POWER
0
7 SOLE DISPOSITIVE POWER
2,826,711 (1)
8 SHARED DISPOSITIVE POWER
0
9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
2,826,711 (1)
10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES  (See Instructions)
☐      
11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
9.9% (2)
12 TYPE OF REPORTING PERSON  (See Instructions)
OO
         
(1)The shares are held of record by Vivo Capital Fund VIII, L.P., and Vivo Capital Surplus Fund VIII, L.P. Vivo Capital VIII, LLC is the general partner of both Vivo Capital Fund VIII, L.P. and Vivo Capital Surplus Fund VIII, L.P.

 

(2)Based on 28,671,849 shares of the Common Stock, par value $0.0001, of the issuer outstanding as of August 3, 2017.

 

 

 

Item 1.(a)Name of Issuer:

 

Amyris, Inc.

 

(b)Address of Issuer’s Principal Executive Offices:

 

5885 Hollis Street, Suite 100, Emeryville, CA 94608

 

Item 2.(a)Name of Person Filing:

 

Vivo Capital VIII, LLC

 

(b)Address of Principal Business Office or, if None, Residence:

 

505 Hamilton Avenue, Suite 207, Palo Alto, CA 94301

 

(c)Citizenship:

 

Vivo Capital VIII, LLC is a Delaware limited liability company.

 

(d)Title of Class of Securities:

 

Common Stock

 

(e)CUSIP Number:

 

03236M101

 

Item 3.If This Statement is Filed Pursuant to §§ 240.13d-1(b), or 240.13d-2(b) or (c), Check Whether the Person Filing is a:

 

(a)☐       Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o);

 

(b)☐       Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c);

 

(c)☐       Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c);

 

(d)☐       Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8);

 

(e)☐       An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);

 

(f)☐       An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);

 

(g)☐       A parent holding company or control person in accordance with § 240.13d-1(b)(l)(ii)(G);

 

(h)☐       A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

 

(i)☐       A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3) ;

 

(j)☐       A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J);

 

(k)☐       Group, in accordance with § 240.13d-1(b)(l)(ii)(K).

 

If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1(ii)(j), please specify the type of institution: ________________

 

Not Applicable.

 

 

  

Item 4.Ownership.

 

(a)       Amount beneficially owned:

 

The shares of Common Stock are held of record by Vivo Capital Fund VIII, L.P. and Vivo Capital Surplus Fund VIII, L.P., as follows:

 

Vivo Capital Fund VIII, L.P.: 2,483,737 shares

 

Vivo Capital Surplus Fund VIII, L.P.: 342,974 shares

 

Vivo Capital VIII, LLC is the general partner of both Vivo Capital Fund VIII, L.P. and Vivo Capital Surplus Fund VIII, L.P. The voting members of Vivo Capital VIII, LLC are Dr. Frank Kung, Dr. Albert Cha, Dr. Edgar Engleman, Dr. Chen Yu and Shan Fu, none of whom has individual voting or investment power with respect to these shares and each of whom disclaims beneficial ownership of such shares.

 

(b)       Percent of class:

 

9.9%

 

(c)       Number of shares as to which such person has:

 

(i)Sole power to vote or to direct the vote: 2,826,711

 

(ii)Shared power to vote or to direct the vote: 0

 

(iii)Sole power to dispose or to direct the disposition of: 2,826,711

 

(iv)Shared power to dispose of or to direct the disposition of: 0

 

Item 5.Ownership of Five Percent or Less of a Class.

 

Not Applicable.

 

Item 6.Ownership of More than Five Percent on Behalf of Another Person.

 

Not Applicable.

 

Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

 

Not Applicable.

 

Item 8.Identification and Classification of Members of the Group.

 

Not applicable.

 

Item 9.Notice of Dissolution of Group.

 

Not applicable.

 

Item 10.Certifications.

 

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a11.

 

 

 

 

SIGNATURE

 

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

       
  Vivo Capital VIII, LLC
   
  August 8, 2017    
  (Date)
   
  /s/ Frank Kung  
  (Signature)
   
  Managing Member  
  (Title)